Inactivation of the von-Hippel Lindau ( VHL ) tumor suppressor gene occurs in 90% of human clear cell renal cell carcinomas (ccRCC) and leads to the stable expression of the hypoxia-inducible factors HIF1α and HIF2α. The constitutive expression of HIF1α in a majority of VHLdefi cient tumors is counterintuitive, given that HIF1α functions as a tumor suppressor in ccRCC, whereas HIF2α clearly enhances tumor growth. We demonstrate here that miR-30c-2-3p and miR-30a-3p specifi cally bind and inhibit expression of HIF2A transcripts, and that the locus encoding miR-30c-2-3p and miR-30a-3p is selectively repressed in "H1H2" VHL -defi cient tumors expressing both HIF1α and HIF2α proteins. Inhibiting miR-30a-3p expression increases HIF2α levels in H1H2 ccRCC cells and promotes cellular proliferation, angiogenesis, and xenograft tumor growth. Our results indicate that miR-30c-2-3p and miR-30a-3p repression enhances HIF2α expression and suggests a mechanism whereby the tumorsuppressive effects of constitutive HIF1α expression are attenuated in VHL -defi cient H1H2 tumors.
INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) is the most commonly diagnosed form of kidney cancer and accounts for the majority of renal cancer-related deaths. A characteristic RESEARCH BRIEF transcription factors consisting of α and β subunits ( 2 ) , and HIFα subunits (HIF1α and HIF2α) are hydroxylated by prolyl hydroxylase (PHD) enzymes, resulting in pVHL recognition, polyubiquitination, and proteasomal degradation ( 3 ) . However, under low oxygen (O 2 ) conditions, HIFα subunits are stabilized, bind the β subunit (ARNT), and activate numerous genes involved in metabolism, angiogenesis, proliferation, cellular motility/invasion, and extracellular matrix remodeling ( 4 ) . Although HIF1α and HIF2α have overlapping functions, recent studies have illustrated remarkably distinct roles for each α isoform in both normal physiology and disease ( 4 ) .
We have previously stratifi ed more than 200 VHL -defi cient ccRCC tumors into two subtypes: one group (∼60% of all cases) expressing both HIF1α and HIF2α (designated "H1H2") and another 30% expressing HIF2α exclusively (designated "H2"; refs. 5, 6 ) . Although HIF2α promotes tumorigenesis ( 7 ), HIF1α has been clearly shown to be a tumor suppressor (8) (9) (10) in this disease. This differential HIFα expression pattern raises an important question: if HIF1α is a tumor suppressor, how do H1H2 ccRCCs evade the inhibitory activities of HIF1α? Delineating the mechanisms by which H1H2 ccRCCs overcome the tumor-suppressive effects of HIF1α could identify novel molecular targets for future ccRCC treatment.
Integrated genomic analyses revealed that H1H2 tumors display enhanced mitogen-activated protein kinase and mTOR signaling, whereas H2 ccRCCs exhibit increased c-Myc activity ( 5, 6 ) . In addition, an important role for microRNAs (miRNA) in ccRCC progression has been suggested ( 11, 12 ) . miRNAs are small, non-coding RNAs (∼22 nucleotides) representing 1% to 2% of the eukaryotic transcriptome that constitute important posttranscriptional regulators of more than 30% of mammalian genes ( 13 ) . miRNAs can act as either oncogenes or tumor suppressors ( 13 ) , and because each miRNA potentially regulates numerous genes, they represent powerful discovery tools to identify novel pathways impacting cancer. To investigate the role of miRNAs in regulating the progression of distinct ccRCC subtypes, we performed miRNA microarray studies on H1H2 and H2 ccRCCs, along with matched normal control tissue samples. We observed preferential repression of multiple miR-30 family members in H1H2 tumors when compared with adjacent kidney tissues, whereas the repression was less pronounced in H2 tumors. Moreover, we further demonstrated that repression of these miRNAs contributes to higher HIF2α levels in H1H2 tumors, apparently as a compensatory mechanism to circumvent the stable expression of HIF1α. Because HIF2α plays a key oncogenic role in ccRCCs, identifi cation of miRNAs that specifi cally target HIF2α is of great importance with potential therapeutic implications for kidney cancer.
RESULTS

miR-30c-2-3p and miR-30a-3p Are Repressed in H1H2 Tumors in a pVHL-Dependent Manner
To identify miRNAs whose differential expression might promote the selective growth and progression of H1H2 or H2 ccRCCs, we performed microarray analysis of RNA from H1H2 ( n = 5) and H2 ( n = 8) tumors, as well as adjacent normal kidney tissue. Signifi cant differences in miRNA levels were observed between tumors and their respective control samples ( Fig. 1A ) .
As expected, levels of the previously identifi ed hypoxia-regulated miR-210 ( 14 ) were elevated in both H1H2 and H2 subtypes. We then focused on miRNAs that were differentially expressed in each ccRCC subtype, and chose miR-30c-2-3p for further analysis, as its expression was signifi cantly more repressed in H1H2 than in H2 tumors when normalized to adjacent normal kidney RNA ( Fig. 1A , arrow; B ) . MIR30C2 maps to human chromosome 6q13, and is closely linked to MIR30A (Supplementary Fig. S1A ). Intriguingly, miR-30a-3p expression was also repressed in H1H2 tumors relative to H2 tumors ( Fig. 1C and Supplementary Fig. S1B, arrows) , suggesting common regulation of the genomic locus. Importantly, analysis of data from The Cancer Genome Atlas (TCGA) revealed that miR-30c-2-3p and miR-30a-3p are signifi cantly repressed in numerous ccRCCs ( n = 437) when compared with normal tissue samples ( n = 68; Fig. 1D and E ) . Moreover, correlation analysis using TCGA data indicated that both miR-30c-2-3p and miR-30a-3p are signifi cantly coregulated in ccRCCs ( n = 437; Supplementary Fig. S1C ).
As both HIF1α and HIF2α are constitutively expressed in H1H2 ccRCCs, we fi rst investigated whether HIFs regulate the expression of miR-30c-2-3p and miR-30a-3p . Inhibition of either HIFα subunit using short hairpin RNA (Supplementary Fig. S2A and S2B) or siRNA (Supplementary Fig. S2C and S2D) techniques demonstrated that miR-30c-2-3p and miR-30a-3p were not regulated by HIF. However, because both miRNAs are repressed in VHL -defi cient ccRCCs, we reintroduced pVHL into RCC10 cells, and observed signifi cant derepression of miR-30c-2-3p and miR-30a-3p ( Fig. 1F ) . Altogether, these studies indicate that the preferential inhibition of miR30c-2-3p and miR-30a-3p observed in H1H2 tumors is pVHLdependent, but HIF-independent.
miR-30c-2-3p/30a-3p Repress HIF2a Expression in H1H2 ccRCCs
We employed bioinformatic tools (ref. 15 ; DianaMicroT) to identify specifi c molecular targets of miR-30c-2-3p and miR30a-3p . Interestingly, both miRNAs were predicted to bind HIF2A transcripts, which we tested by fusing the HIF2A 3′ untranslated region (UTR) to a standard luciferase reporter gene construct. Mutating miR-30c-2-3p or miR-30a-3p seed sequences in the HIF2A 3′ UTR was suffi cient to block miR-30c-2-3p/30a-3p -dependent regulation of luciferase activity ( Fig. 2A and B and Supplementary Fig. S3A ). We selected RCC4, RCC10, and UMRC2 ccRCC cell lines for further functional analyses, as they stably express both HIF1α and HIF2α. Ectopic expression of miR-30c-2-3p (miR-30c-2-3p EE) in RCC4 and RCC10 cells decreased HIF2A mRNA expression ( Fig. 2C and Supplementary Fig. S3B ), whereas miR-30c-2-3p inhibition (miR-30c-2-3p INH) increased HIF2A transcript levels ( Fig. 2D ). HIF2α protein levels were similarly reduced by ectopic expression of miR-30c-2-3p and increased by miR-30c-2-3p inhibition in both RCC4 and RCC10 cells ( Fig. 2E ) , with consequent effects on the expression of HIF2α-regulated target genes, including VEGF , GLUT1 , and TGFA ( Fig. 2F and Supplementary  Fig. S3C and S3D ). To confi rm that miR-30a-3p also regulates HIF2α, we stably inhibited miR-30a-3p and found elevated HIF2α abundance in RCC4 and UMRC2 cells ( Fig. 2G and Supplementary Fig. S3E ). In each of these studies, expression levels of HIF1α, and its transcriptional target phosphoglycerate kinase 1 ( PGK1 ), were not altered by miR-30c-2-3p or As stated above, recent studies have confi rmed that HIF1α acts as a tumor suppressor in ccRCCs ( 10 ); however, 60% of ccRCCs constitutively express HIF1α ( 5, 6 ). We hypothesized that repression of miR-30c-2-3p and miR-30a-3p ameliorates the suppressive effects of HIF1α by elevating relative HIF2α expression in VHL -defi cient ccRCCs. To test this hypothesis, we fi rst analyzed the basal expression of HIF2A in clinical ccRCC samples using TCGA data and observed signifi cantly increased HIF2A levels relative to normal renal tissue ( Fig. 2H ) . Because miR-30c-2-3p and miR-30a-3p are preferentially repressed in H1H2 tumors, we investigated whether HIF2A mRNA levels are signifi cantly elevated in H1H2 tumors, compared with H2 tumors. To fi rst identify H1H2 and H2 tumors among the TCGA ccRCC dataset, we fi rst performed copy number (CN) analysis to determine the status of VHL and HIF1A . On the basis of this approach (see Methods), approximately 77% (373/470) of TCGA ccRCC samples were inferred to have VHL loss. Of these, approximately 30% also displayed a CN value for HIF1A of <1.6, signifying gene deletion ( Supplementary Fig. S3I ). These samples were confi rmed as having hemizygous HIF1A deletions by independent analyses using cBioPortal for Cancer Genomics (Memorial Sloan-Kettering Cancer Center, New York, NY). On the basis of these criteria, we designated VHL -defi cient ccRCC samples with CN <1.6 at HIF1A as the "H2" subtype ( n = 110/362; Supplementary Fig. S3I ), whereas VHL -defi cient tumors expressing both HIFα isoforms were designated as the "H1H2" group ( n = 252/362). It should be emphasized that this stratifi cation is based solely on VHL mutations/deletions and HIF1A deletions, and does not include other forms of genomic alteration that could reduce expression, such as aberrant DNA methylation or altered chromatin structure. Despite this limitation, our classifi cation system was consistent with the stratifi cation based on HIF1α and HIF2α immunohistochemical staining, where approximately onethird of VHL-defi cient ccRCCs were defi ned as H2 tumors ( 5, 6 ) . Importantly, our analysis of the stratifi ed TCGA ccRCC samples revealed signifi cantly higher HIF2A transcript levels in H1H2 tumors, relative to H2 ccRCCs ( Fig. 2I ). In addition, we measured HIF2A transcript levels in University of Pennsylvania (UPENN; Philadelphia, PA) ccRCC samples that were previously stratifi ed into H1H2 and H2 subtypes by immunohistochemical staining for HIF1α and HIF2α ( 5, 6 ) . Consistent with our results using the TCGA dataset, the UPENN ccRCC H1H2 tumors displayed higher HIF2A
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expression levels than the H2 tumors ( n = 11 each; Fig. 2J ), supporting our hypothesis that elevating HIF2α expression is a general mechanism whereby H1H2 ccRCCs compensate for the tumor-suppressive activities of HIF1α.
HIF2a Is a Critical Target of miR-30c-2-3p in ccRCC
Our data suggest that increased HIF2α protein levels are a primary functional consequence of miR-30c-2-3p/miR-30a-3p repression in H1H2 ccRCCs. To test this hypothesis directly, we transiently expressed miR-30c-2-3p/miR-30a-3p in the UMRC2 ccRCC cell line. Ectopically expressed miR-30c-2-3p inhibited UMRC2 proliferation during in vitro cell culture; however, no proliferative effect was observed with increased miR-30a-3p expression ( Supplementary Fig. S4 ). Similarly, miR-30c-2-3p expression reduced the ability of UMRC2 cells to form colonies in vitro ( Fig. 3A and B and Supplementary Figs. S5A and  S6A ). This effect was amplifi ed when cells were fi rst exposed to serum-and glucose-free conditions for 48 hours, followed by growth under serum-and glucose-replete conditions for 12 days ( Fig. 3A and B ) . ( Fig. 3C ) . Similar results were obtained for the H2 ccRCC cell lines 786-0 and 769-P ( Supplementary  Fig. S6B and S6C) . To determine the HIF2α dependence of these responses, a HIF2A open reading frame ( Supplementary  Fig. S5C ) was introduced into UMRC2 cells expressing either miR-30c-2-3p or a miR-SCR control construct. We observed that ectopic HIF2α expression signifi cantly reversed the miR-30c-2-3p -mediated phenotypes in these assays ( Fig. 3A-D ) . Collectively, these studies specifi cally illustrate that HIF2α is an important target of miR-30c-2-3p in ccRCC cells, and suggest that miR-30c-2-3p repression enhances HIF2α activity in H1H2 tumors, at the expense of HIF1α.
Modulation of miR-30c-2-3p and miR-30a-3p Expression Affects Tumor Growth and Predicts Human ccRCC Patient Survival
On the basis of our in vitro results, we fi rst analyzed whether increased expression of miR-30c-2-3p and miR-30a-3p affects in vivo tumor growth. As UMRC2 cells reproducibly generate subcutaneous xenograft tumors ( 10 ), we injected immunocompromised (Nu/Nu) mice subcutaneously with UMRC2 cells ectopically expressing either miR-30c-2-3p , miR-30a-3p , or a scrambled control. Increased expression of either miR-30c-2-3p or miR-30a-3p signifi cantly inhibited xenograft tumor growth when compared with the control group ( Fig. 4A and Supplementary Fig. S5A and S5B) . Therefore, we postulated that miR-30c-2-3p or miR-30a-3p inhibition would enhance ccRCC tumor growth in vivo . However, as noted above, the abundance of these miRNAs is already signifi cantly repressed in ccRCC cells, making it potentially diffi cult to further reduce their expression. Given that basal miR-30a-3p levels are higher than miR-30c-2-3p in UMRC2 cells, we focused on the functional outcome of inhibiting miR-30a-3p in these cells. We injected immunocompromised (Nu/Nu) mice subcutaneously with UMRC2 cells expressing either a miR30a-3p antagomir ( miR-30a-3p INH) or a scrambled control ( miR -SCR INH; Fig. 4B and Supplementary Fig. S7A and S7B). Importantly, tumors derived from the miR-30a-3p INH cells were signifi cantly larger than controls ( Fig. 4B and -30c-2-3p or miR-30a-3p expression in patients with ccRCC (TCGA). " miR-30c-2-3p low" ( n = 143) represents the bottom one-third of the cases, whereas " miR-30c-2-3p high" ( n = 286) is designated as the top two-thirds of the samples. Log-rank test was used to assess statistical signifi cance. Similar classifi cation was used for performing survival analysis based on miR-30a-3p levels. K, proposed model illustrating the role of miR-30c-2-3p and miR-30a-3p in modulating HIF2α levels in ccRCC tumors. For all statistical analyses: *, P < 0.05; **, P < 0.005; ***, P < 0.0005. Data, mean ± SEM. Research.
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on January 20, 2018. © 2014 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from Supplementary Fig. S7A and S7B ). Histologic analyses also revealed mild to moderate degenerative changes in tumors from the miR-SCR INH group, a feature not observed in miR-30a-3p INH tumors (Supplementary Fig. S7C ). Immunohistochemical staining for Ki67 demonstrated increased cell proliferation in miR-30a-3p INH tumors compared with miR-SCR INH tumors ( Fig. 4C ) . Of note, the effect of miR-30a-3p on cell proliferation is very similar to HIF2α, where increased miR-30a-3p expression (Supplementary Fig. S4 ) or HIF2α inhibition did not affect cell growth in vitro , but inhibited tumor growth in vivo ( 7 ) . Although no signifi cant difference in tumor blood vessel area was observed between the two cohorts, as refl ected by the number of CD31 + endothelial cells ( Fig. 4D and G ) , vessel coverage by smooth muscle actinexpressing (SMA+) pericytes was signifi cantly increased in miR-30a-3p INH tumors ( Fig. 4D and E ) , suggesting that these vessels are more mature ( Fig. 4F ) . Furthermore, we observed increased HIF2α protein expression in miR-30a-3p -inhibited tumors compared with the miR-SCR INH group ( Fig. 4H ) , suggesting that elevated HIF2α levels contribute directly to the tumor angiogenesis and cell proliferation phenotypes in miR-30a-3p INH tumors. These results are also consistent with previous reports, indicating that HIF2α expression is positively associated with ccRCC cell proliferation and tumor angiogenesis ( 16 ) .
Finally, we determined whether miR-30c-2-3p and miR-30a-3p expression levels correlate with human ccRCC patient survival. Reduced expression of either miR-30c-2-3p or miR-30a-3p was signifi cantly associated with poor prognosis in patients with ccRCC ( Fig. 4I and J ) , suggesting that their repression is important for ccRCC growth and/or progression. Collectively, our studies illustrate a novel compensatory mechanism whereby tumor cells alter miRNA expression to increase the abundance of an oncoprotein, HIF2α.
DISCUSSION
Biallelic VHL inactivation leads to an increased abundance of HIF1α and HIF2α in ccRCCs, and compelling evidence suggests that HIF2α, rather than HIF1α, promotes pVHLdefi cient ccRCC tumorigenesis ( 17 ) . However, nearly two-thirds of VHL -mutant ccRCCs express HIF1α ( 5, 6 ), prompting us to investigate the molecular mechanisms that overcome the previously characterized tumor-suppressive activity of HIF1α in these tumors. Although the role of various miRNAs has been documented in ccRCCs ( 12 ) , the major goal of our study was to identify miRNAs that are preferentially altered in H1H2 versus H2 subtypes. This analysis gave us a unique opportunity to probe novel molecular pathways that are distinct between the two ccRCC groups. We demonstrate here that HIF2α expression is elevated in H1H2 tumors, and propose that preferential repression of miR-30c-2-3p and miR30a-3p in the H1H2 subclass contributes signifi cantly to this phenotype.
miR-30c-2-3p and miR-30a-3p are located on chromosome 6q13, and our data suggest that their expression is pVHL dependent, but HIF independent. Similar to our results, miR-204 is also repressed in VHL -defi cient ccRCCs, and positively regulated by pVHL independent of HIF activity ( 11 ) . Although pVHL stimulates miR-204 , miR-30c-2-3p , and miR-30a-3p expression, it is likely that additional intermediate factors are involved. pVHL clearly affects the activity of multiple transcription factors, including NF-κB ( 18 ) and β-catenin ( 19 ) . Of note, GATA3 regulates miR-30c-2-3p transcription in breast tumor cells ( 20 ) , and GATA3 expression is decreased in all stages of ccRCC (see Supplementary Fig. S8 ), due to epigenetic silencing ( 21 ) . Therefore, it is plausible that loss of GATA3 in ccRCCs is responsible for reduced miR-30c-2-3p and miR-30a-3p levels in VHL -defi cient ccRCCs.
In addition to the modulation of HIF2α levels by miRNA repression, alternative mechanisms favoring enhanced HIF2α activity have been described previously. Factor inhibiting HIF1 (FIH1) is an oxygen-dependent enzyme that hydroxylates an asparaginyl residue in its C-terminal transactivation domain (CTAD), preventing the recruitment of coactivator proteins required for transcriptional activity ( 22 ) . However, HIF2α is less sensitive to FIH1-mediated inhibition than HIF1α ( 23 ), resulting in a relative increase in HIF2α target gene expression. In addition, HIF1α undergoes preferential proteasomal degradation in the absence of pVHL, possibly via distinct ubiquitin ligases or direct interaction with the proteasome ( 24 ) . These fi ndings clearly suggest that HIF2α abundance is critical for ccRCC tumorigenesis, and miR30c-2-3p and miR-30a-3p repression represents a novel means whereby tumor cells antagonize the tumor-suppressive role of HIF1α ( Fig. 4K ) .
A more general role for miRNAs has been demonstrated in numerous cancers (including ccRCCs), suggesting that the development of miRNA-based therapies could ultimately be benefi cial for patient care. Systemic miR-26a delivery using adeno-associated virus inhibits the progression of hepatocellular carcinoma in mice, illustrating the potential utility of these biomolecules in disease treatment ( 25 ) . Although some progress has been made in miRNA delivery, the use of synthetic miRNAs for renal tumor therapy is still in its infancy. Because miR-30c-2-3p and miR-30a-3p directly regulate HIF2α, which acts as an oncoprotein in ccRCC, these miRNAs represent novel therapeutic agents of the future. In conclusion, we demonstrate a novel molecular mechanism by which HIF2α levels are elevated to compensate for the inhibitory effects of HIF1α in VHL -defi cient H1H2 ccRCCs.
METHODS
Cell Culture
The human RCC cell lines RCC4 and 786-0 were obtained from the American Type Culture Collection. RCC10, UMRC2, and 769-P cells were a kind gift from Dr. W.G. Kaelin (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA). These cells were cultured in Dulbecco's Modifi ed Eagle Medium containing 10% FBS and antibiotics. All cell lines were verifi ed for VHL and HIFα expression status using quantitative PCR and Western blot analysis within the last 6 months.
ccRCC Patient Samples
For performing microarray analysis, frozen tumor samples were obtained from the Hospital of UPENN. Samples were embedded at optimum cutting temperatures and sectioned for RNA extraction. The protocols used were approved by the Institutional Review Board of University of Pennsylvania.
Other information on methods is described in the Supplementary Data.
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